Induced Pluripotent Stem Cells

Companies Induced Pluripotent Stem Cells

BlueRock Therapeutics, USA

BlueRock Therapeutics is a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics’ CELL+GENE™ platform harnesses the power of cells for new medicines across neurology, cardiology and immunology indications. BlueRock Th more

News Induced Pluripotent Stem Cells

• Customized programming of human stem cells
  

  Induced pluripotent stem cells (iPS) have the potential to convert into a wide variety of cell types and tissues. However, the "recipes" for this conversion are often complicated and difficult to implement. Researchers at the Center for Regenerative Therapies Dresden (CRTD) at TU Dresden, Harvard Un more

• Midbrain organoids for automated chemical screening and disease research
  

  Sometimes hundreds of thousands of potential therapeutics need to be tested in large-scale, fully automated experiments to identify a single effective drug. Most compounds do not work as desired, and some are even toxic. Since the development of the induced Pluripotent Stem (iPS) Cell technology in more

• Generation of human brain organoids with the ability to learn
  

  The brain is one of the most complex organs in the human body. Complexity of the brain is the result of highly and dynamically interconnected neurons as well as supporting glia. Lifelong changes in neuronal interconnectivity are key for memory and learning. Disturbances in neuronal interconnectivity more

Publications Induced Pluripotent Stem Cells

• Retraction: Matrix Metalloproteinase-3 in Odontoblastic Cells Derived from Ips Cells: Unique Proliferation Response as Odontoblastic Cells Derived from ES Cells

  by The PLOS ONE Editors more

• [In Depth] iPS cell therapy reported safe

  Japanese researchers reported this week that the first trial of induced pluripotent stem (iPS) cells in a human has proved safe and effective in halting the progression of age-related macular degeneration (AMD), though there was minimal improvement in vision. AMD is the leading cause of vision loss more

• Highly efficient biallelic genome editing of human ES/iPS cells using a CRISPR/Cas9 or TALEN system

  Abstract Genome editing research of human ES/iPS cells has been accelerated by clustered regularly interspaced short palindromic repeats/CRISPR-associated 9 (CRISPR/Cas9) and transcription activator-like effector nucleases (TALEN) technologies. However, the efficiency of biallelic genetic engineeri more